AAP
NPCE icon

Arax Advisory Partners’s Neuropace NPCE Stock Holding History

Arax Advisory Partners’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.94K Buy
+122
New +$1.96K ﹤0.01% 4815

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Arax Advisory Partners's NPCE Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Neuropace (NPCE) in Q2 2026: 122 shares worth $1.94K. The stake represents ﹤0.01% of the portfolio and ranks #4815 among its holdings.

113 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.

  • Arax Advisory Partners held 122 shares of Neuropace worth $1.94K as of Q2 2026.
  • Neuropace was a new Arax Advisory Partners position in Q2 2026.
  • Neuropace made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4815 holding.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.